8
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T1564 | Cisplatin | cis-Diaminodichloroplatinum,CDDP | DNA Alkylator/Crosslinker , Ferroptosis , DNA/RNA Synthesis , Autophagy |
Cisplatin (CDDP) is a DNA cross-linking agent. Cisplatin has antitumor activity and inhibits DNA synthesis by forming DNA adducts in cancer cells. Cisplatin also activates iron death and induces autophagy. | |||
T78227 | L-Methioninamide hydrochloride | DNA/RNA Synthesis | |
L-Methioninamide hydrochloride is a potent inhibitor of methionyl-tRNA synthetase that reduces the toxicity of CDDP. | |||
T3867 | Alpinetin | (-)-alpinetin | BCL , PPAR |
Alpinetin ((-)-alpinetin) has antibacterial activity.Alpinetin has anti-inflammatory activity.Alpinetin can enhance the sensitivity of HepG2 hepatoma cells to the chemotherapeutic agent CDDP. Alpinetin has strong anti-he... | |||
T16351 | NSC16168 | Estrogen/progestogen Receptor | |
NSC16168 inhibits DNA repair and potentiates CDDP efficacy in cancer. NSC16168 is a specific ERCC1-XPF inhibitor (IC50: 0.42 μM). | |||
T30095 | APG-1387 | SM 1387,SM-1387,SM1387,APG 1387l | |
APG-1387 (SM-1387) is an IAP inhibitor that promotes the rapid degradation of cIAP1/2 and XIAP and exerts an anti-tumor effect on nasopharyngeal carcinoma stem cells. Studies have shown that APG-1387 combined with NPC's ... | |||
T39594 | AKR1B10-IN-1 | AKR1B10-IN-1 | |
AKR1B10-IN-1, a powerful AKR1B10 (Aldo-Keto Reductase 1B10) inhibitor, demonstrates an IC50 value of 3.5 nM. This compound effectively curtails the proliferation, metastasis, and Cisplatin (CDDP) resistance of lung cance... | |||
T74491 | Antitumor agent-61 | ||
Antitumor agent-61 (Compound 9b), an Irinotecan (Ir) derivative, demonstrates potent anticancer activity, as evidenced by its IC50 values ranging from 0.92 to 3.23 μM against six human cancer cell lines: SK-OV-3, SK-OV-3... | |||
T74844 | Antiproliferative agent-23 | ||
Antiproliferative agent-23, a microtubule-destabilizing agent (MDA), disrupts the tubulin-microtubule system, leading to apoptosis through a mitochondrion-dependent pathway. This involves downregulation of Bcl-2 protein,... |